[Screening and prevention of toxic optic neuropathies due to anti-mycobacterium therapies: proposal of recommendations]

J Fr Ophtalmol. 2022 May;45(5):495-503. doi: 10.1016/j.jfo.2021.08.016. Epub 2022 Apr 13.
[Article in French]

Abstract

While treatment of pulmonary infections by Mycobacterium tuberculosis is currently only rarely the cause of iatrogenic complications, treatment of atypical mycobacterial infections often requires prolonged treatment duration, which can lead to toxic optic neuropathies. This review summarizes the indications for such prolonged treatment and risk factors for toxic optic neuropathies when using ethambutol, isoniazid and/or linezolid and proposes customized screening recommendations.

Keywords: Atypical mycobacteria; Dépistage; Ethambutol; Isoniazid; Isoniazide; Linezolid; Linézolide; Mycobactérie atypique; Neuropathie optique toxique; OCT; Screening; Toxic optic neuropathy; Tuberculose; Tuberculosis; Éthambutol.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / adverse effects
  • Ethambutol* / adverse effects
  • Humans
  • Isoniazid
  • Linezolid / adverse effects
  • Toxic Optic Neuropathy*

Substances

  • Antitubercular Agents
  • Ethambutol
  • Linezolid
  • Isoniazid